title: Factors predicting morbidity following hematopoietic stem cell transplantation.
abstract: Circulating anticoagulants protein C (PC) and antithrombin III (AT) are markers of, and possibly involved in the pathogenesis of, significant organ dysfunction, in patients undergoing autologous peripheral blood stem cell (PSBC) or autologous bone marrow (BM) transplantation. The effect of the stem cell source, the use of hematopoietic growth factors (GFs), and the specific preparative regimen on the incidence of organ system dysfunction or on post-transplant levels of circulating anticoagulants has not been well studied. We analyzed 205 patients in an attempt to correlate organ dysfunction and AT and PC deficiencies with these transplant-specific factors (78 BMT with GM-CSF after transplant, 95 PBSCT without GM-CSF after transplant, and 32 PBSCT with GM-CSF after transplant). Patients transplanted with PBSC had a lower incidence of pulmonary dysfunction (20 vs 40%, P = 0.006) and liver dysfunction (4 vs 13%, P = 0.05) than patients receiving BM. The use of GF after transplant did not influence the development of subsequent organ dysfunction. In multivariate analysis, the stem cell source was again predictive of pulmonary dysfunction. In contrast, although patients transplanted with PBSC also had a lower incidence of PC deficiency (50 vs 81%, P < 0.01) and AT deficiency (20 vs 54%, P < 0.01) as compared with patients receiving BM, use of GM-CSF after transplant was a more significant risk factor for the development of anticoagulant deficiency (PBSC with GF vs PBSC without GF: PC deficiency 50 vs 78%, P = 0.007; AT deficiency 20 vs 47%, P = 0.005). In the multivariate analysis GM-CSF use was the only significant risk factor for development of anticoagulant deficiency. Since the clinical significance of anticoagulant deficiency has been well shown, further studies examining these effects of hematopoietic GFs appear warranted.
authors.affiliation: Department of Pediatrics, University of Nebraska Medical Center, Omaha 68198-2168, USA.
authors.forename: B
authors.initials: B
authors.lastname: Gordon
authors.forename: W
authors.initials: W
authors.lastname: Haire
authors.forename: E
authors.initials: E
authors.lastname: Ruby
authors.forename: G
authors.initials: G
authors.lastname: Kotulak
authors.forename: L
authors.initials: L
authors.lastname: Stephens
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
authors.forename: J
authors.initials: J
authors.lastname: Armitage
mesh_terms: D020152:Antithrombin III Deficiency; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000209:etiology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002493:Central Nervous System Diseases / Q000097:blood / Q000209:etiology*; D015331:Cohort Studies; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008107:Liver Diseases / Q000097:blood / Q000209:etiology*; D008171:Lung Diseases / Q000097:blood / Q000209:etiology*; D008297:Male; D009102:Multiple Organ Failure / Q000097:blood / Q000209:etiology*; D009369:Neoplasms / Q000628:therapy; D020151:Protein C Deficiency; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000009:adverse effects
chemical_list: D016178:Granulocyte-Macrophage Colony-Stimulating Factor